{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:17:08Z","timestamp":1793661428074,"version":"4.5.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.urology.2019.08.054","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T19:42:03Z","timestamp":1571168523000},"page":"32-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Predictors of Poor Response and Adverse Events Following Botulinum Toxin-A for Refractory Idiopathic Overactive Bladder"],"prefix":"10.1016","volume":"135","author":[{"given":"Mohammad","family":"Abrar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Stroman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Malde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eskinder","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2019.08.054_bib0001","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","article-title":"Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European Consensus Report","volume":"55","author":"Apostolidis","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2019.08.054_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147137","article-title":"Factors associated with therapeutic efficacy of intravesical onabotulinumtoxinA Injection for overactive bladder syndrome","volume":"11","author":"Hsiao","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.urology.2019.08.054_bib0003","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.eururo.2010.09.007","article-title":"Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome","volume":"58","author":"Kuo","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2019.08.054_bib0004","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1464-410X.2008.08076.x","article-title":"Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?","volume":"103","author":"Sahai","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2019.08.054_bib0005","first-page":"24","article-title":"Validation of the urogenital distress inventory (UDI-6) and incontinence impact questionnaire (IIQ-7) in a Dutch population","volume":"34","author":"Utomo","year":"2015","journal-title":"NeurourolUrodyn"},{"key":"10.1016\/j.urology.2019.08.054_bib0006","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.urology.2018.09.016","article-title":"Onabotulinum toxin a injections in men with refractory idiopathic detrusor overactivity","volume":"123","author":"Faure Walker","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.urology.2019.08.054_bib0007","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of OnabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2019.08.054_bib0008","doi-asserted-by":"crossref","unstructured":"Denys P, Le Normand L, Ghout I, et al. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol. 2012;61:520\u2013529.","DOI":"10.1016\/j.eururo.2011.10.028"},{"key":"10.1016\/j.urology.2019.08.054_bib0009","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/nau.21021","article-title":"Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder","volume":"30","author":"Rovner","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2019.08.054_bib0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/nau.20611","article-title":"Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units","volume":"28","author":"Cohen","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2019.08.054_bib0011","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/nau.22642","article-title":"Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome","volume":"34","author":"Osborn","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2019.08.054_bib0012","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.juro.2012.11.089","article-title":"Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity","volume":"189","author":"Liao","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2019.08.054_bib0013","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2147\/IJWH.S55383","article-title":"Prevention and management of postoperative urinary retention after urogynecologic surgery","volume":"6","author":"Geller","year":"2014","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.urology.2019.08.054_bib0014","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1046\/j.1464-410X.2003.04135.x","article-title":"Urinary retention after hysterectomy for benign disease: extended diagnostic evaluation and treatment with sacral nerve stimulation","volume":"91","author":"Everaert","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2019.08.054_bib0015","first-page":"1235","article-title":"Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxina injection in patients with refractory detrusor overactivity","volume":"33","author":"Wang","year":"2014","journal-title":"NeurourolUrodyn"},{"key":"10.1016\/j.urology.2019.08.054_bib0016","first-page":"217","article-title":"Refractory idiopathic urge urinary incontinence and botulinum a injection","volume":"180","author":"Brubaker","year":"2008","journal-title":"The JUrol"},{"key":"10.1016\/j.urology.2019.08.054_bib0017","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.urology.2007.11.039","article-title":"Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder","volume":"71","author":"Sahai","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.urology.2019.08.054_bib0018","series-title":"EAU Guidelines on Urinary Incontinence","author":"Burkhard","year":"2018"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429519308805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429519308805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:05:02Z","timestamp":1758765902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429519308805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":18,"alternative-id":["S0090429519308805"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2019.08.054","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of Poor Response and Adverse Events Following Botulinum Toxin-A for Refractory Idiopathic Overactive Bladder","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2019.08.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}